Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

• the invention relates to monoclonal antibodies with superior therapeutic value.
• the antibodies of the invention are particularly selective for cancer cells, and more particularly for cancer cells that secrete certain autocrine growth factors.
• a family of receptors that mediate signaling through tyrosine kinases includes a subfamily of at least four members: HERl also designated epidermal growth factor receptor (EGFR) is encoded by the ErbBl gene; HER2 or HER2/neu encoded by the ErbB2 gene, HER3, encoded by the ErbB3 gene and HER4, encoded by ErbB4.
• EGFR epidermal growth factor receptor
• the primary natural ligand for the receptor encoded by ErbB3 is heregulin (HRG), a polypeptide that, when bound to HER3 induces a conformational change that promotes dimerization of HER3 with HER2 through the extracellular domains of each activating the signaling cascade, as shown in Figure IA.
• HRG The primary natural ligand for the receptor encoded by ErbB3
• EGF Epidermal Growth Factor
• Antibodies including monoclonal antibodies to HER3 have been prepared.
• U.S. 5,480,968 discloses antibodies that bind specifically to ErbB3 and do not bind to ErbB2 or ErbB 1.
• U.S. Patent No. 5,968,511 discloses and claims antibodies that bind to HER3 and reduce heregulin- induced formation of an HER2-HER3 protein complex in cells that express both of these receptors or which antibodies increase the binding affinity of heregulin for ErbB3 protein or which reduce activation of the downstream signaling. Although only murine antibodies are prepared, humanized antibodies are also claimed.
• Published U.S. application 2004/0197332 describes and claims anti-HER3 antibodies that downregulate the expression of HER3.
• PCT Publication WO2007/077028 describes antibodies that bind to HER3 that are produced in XenoMouse ® and are thus fully human by sequence. Most of these antibodies are described as binding to the major ligand binding domain (L2) of the extracellular domain of HER3, but the binding is destroyed if the three-dimensional structure of the extracellular domain is disrupted. Further, the antibodies described in this publication compete with HRG for binding to HER3.
• Figures IA and IB are diagrams of the interaction of HER2 and HER3 in the presence of heregulin ( Figure IA) and in the presence of both heregulin and either antibody 14B10 or antibody 1G4 ( Figure IB).
• Figures 2A and 2B are graphs showing a comparison of binding of 1G4 mAb and 14B10 mAb to the heregulin active complex with HER3 as measured by ForteBio ® biosensor.
• Figures 3 A and 3B show the ability of various antibodies directed against HER3 to inhibit the growth of MCF-7 carcinoma cells and to inhibit tyrosine phosphorylation in these cells.
• Figure 4 shows the ability of various anti-HER3 antibodies to inhibit MCF-7 cell proliferation.
• Figure 5 shows that activity by the tyrosine phosphorylation measure of activity is not predictive of anti-proliferative activity.
• Figure 6 shows the ability of various antibodies directed against HER3 to inhibit tyrosine proliferation in MB 468, a cell line that over-expresses HERl and HER3 rather than HER2 and HER3.
• Figure 7 shows the nucleotide sequence encoding 1G4 heavy chain (SEQ ID NO:
• the present invention provides monoclonal antibodies with unique specificities for the heregulin-bound active form of HER3, thus, preferentially inhibiting dimerization and downstream signaling in environments with high concentrations of heregulin.
• Such high concentrations characterize many tumor cells.
• toxicities arising from blocking signaling from lower concentrations in normal cells can be minimized (Bria, E, et al, Expert Opin Biol Ther. (2008) 8:1963-1971).
• antibodies that preferentially bind a HER3 :heregulin complex is advantageous since they are most effective on cells, such as cancer cells that are dependent on the complex signaling for growth. This type of cell is characteristic of many tumors.
• the invention is directed to monoclonal antibodies and pharmaceutical compositions thereof wherein these antibodies bind to heregulin activated HER3 with an affinity at least five times their affinity for HER3 not bound to heregulin, preferably ten times greater, at all values between 5 and 10, and at values greater than 10.
• the affinity of the antibody will be at least that represented by a kD of 5 nM for HER3 itself, more preferably that represented by a kD of at least 2 nM and more preferably that represented by a kD of lOO pmol.
• the monoclonal antibodies may take many forms, including chimeric forms wherein the variable regions are of one species and the constant regions of another; forms consisting only of the variable regions, single-chain forms; and the like.
• antibodies refers both to whole antibodies and to fragments thereof that exhibit the required immunospecificity. In some cases, this is spelled out, but if not, fragments are intended to be included in this term unless it is otherwise obvious from context.
• the antibodies of the invention can be obtained by extensive screening of hybridomas or immortalized cells of laboratory animals such as rats, mice and rabbits immunized with appropriate immunogens.
• Appropriate immunogens include those exemplified below, as well as portions of the HER3 protein that have been treated with heregulin.
• the antibodies thus produced are screened for their ability to bind heregulin-bound HER3 differentially from HER3 itself. These antibodies can then be humanized using procedures now commercially available to obtain antibodies suitable for administration to humans.
• an antibody with this desirable differential binding affinity 1G4 was prepared. Humanized forms and human analogs of this antibody are included within the scope of this invention.
• the hybridoma that produces IG4 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110, under the terms of the Budapest Treaty on 29 April 2010. Upon issuance of a U.S. patent disclosing this hybridoma, all restrictions on this deposit will be irrevocably removed.
• Figure 7 shows the nucleotide sequence and amino acid sequences of the heavy chain and light chain of 1G4 respectively.
• the CDR of the heavy chain are:
• CDRHl GYTFTDYVS (SEQ ID NO: ); CDRH2:IYPSGRY (SEQ ID NO: );
• CDRH3:TRSLQRLRYFDV (SEQ ID NO: ).
• the CDR of the light chain are
• CDRLl RASQSISDYLH (SEQ ID NO: ); CDRL2:YGSQSIS (SEQ ID NO: );
• CDRL3 QQSNSWPLT (SEQ ID NO: ).
• laboratory animals that produce human antibodies directly can be used as subjects to produce antibodies that are human.
• the immunogen can be administered to animals such as the XenoMouse ® that will provide directly the human antibodies desired. These antibodies are screened in a manner similar to that employed in screening hybridomas or other immortalized rodent cells.
• Suitable antibodies can also be obtained directly from human beings, since individuals harboring tumors, for example, that produce heregulin :HER3 complexes will generate antibodies to these tumor antigens.
• antibodies immunospecific for tumor antigens are produced by such subjects. See, for example, Pavoni, E., et ah, BMC Biotechnology (2007) 770: 1-17.
• patients with autoimmune diseases such as lupus make antibodies to cell antigens not necessarily associated with tumors. Because of the large number of cells that can be sampled, even very rare antibodies can be obtained in this fashion.
• the antibodies can then be produced recombinantly using well known techniques.
• the nucleotide sequences encoding the antibodies are obtained from cells secreting them and suitable expression constructs prepared to transfect host cells for such recombinant production.
• suitable expression constructs prepared to transfect host cells for such recombinant production.
• the ability to produce such antibodies recombinantly permits variants such as single chain antibodies to be produced.
• a variety of cells can be used for such production including insect, mammalian and plant cells, as well as microorganism cultures.
• the antibodies of the invention, and fragments thereof, in particular, human and humanized forms of them, are useful in treating cancers that are associated with heregulin-stimulated signaling. These include cancers of the breast, uterus, ovary, prostate, kidney, lung, pancreas, stomach, salivary gland, colon, colon-rectal, thyroid, bladder, skin, or any cancer exhibiting heregulin-stimulated proliferation. It may be useful to evaluate the cancer to be treated for its ability to secrete heregulin in connection with conducting treatment using the antibodies of the invention. This may be done by culturing cells from a biopsied cancer sample or by in situ testing of the tumor in vivo. In one method, this is done by contacting said tumor or biopsy thereof with the antibodies or fragments of the invention and determining the level of complex formed as compared to any complex formed with antibodies that bind to uncoupled HER3.
• the subjects may be human or veterinary, including, domestic animals such as dogs and cats, farm animals such as pigs, cows and sheep; and laboratory model animals such as rats, mice and rabbits.
• Laboratory model animals may be particularly useful in evaluating the effect of the antibodies of the invention in the corresponding human tumors, and such use is included within the invention.
• the antibodies of the invention may also be coupled to cytotoxic agents and/or to anti-tumor drugs in general.
• cytotoxic agents include, for example, platinum-based drugs, cell cycle inhibitors, natural products such as vincristine and various camptothecins.
• the antibodies are formulated according to standard procedures for pharmaceutical compositions of antibodies such as those described in Remington's Pharmaceutical Sciences. Mack Publishing Company, Easton PA, latest edition. These formulations may include delivery vehicles such as liposomes or micelles or may contain standard excipients, such as saline or saccharides. [0032] Typically, the antibody compositions are administered by injection, in particular intravenous injection. However, any mode of administration that is workable with such compositions is included within the scope of the invention.
• the production of the antibodies on a practical scale may include standard recombinant methods wherein the nucleotide sequences encoding the antibodies or portions thereof have been isolated and manipulated in standard procedures to obtain the active antibody compositions. Such production is typically in mammalian cell culture, insect cell culture or plant cell culture or may be by plants per se.
• the antibodies of the claimed characteristics are included within the scope of the inventions regardless of means of production.
• Seven murine hybridoma libraries were prepared by immunizing mice with 293 cells overexpressing HER3 extracellular domain (ECD) along with a polypeptide which consists essentially of the L2 domain of HER3 that had been produced in E. coli, and fusion of the immunized B cells with a murine myeloma by standard methods. About 400 million hybridoma cells were screened for immunoactivity with HER3 in the presence and absence of heregulin, of which about 700 were positive for binding to both by initial ELISA assay and about 70 by FACS analysis for binding to intact cells. The screening employs the assays in the above cited U.S. 7,413,868.
• 14B10 showed the highest affinity but all of the six antibodies bound in the pM or nM range.
• Antibody 14B10 bound to HER3 :heregulin complex at about the same affinity as to HER3.
• Antibody 1G4 bound to HER3 alone with an affinity of 2.8 nM, but to the HER3 :heregulin complex with an affinity of 327 pM. In both cases, the binding affinity for HER3 was tighter than that of heregulin itself which binds to HER3 ECD with an affinity of 165 nM.
• FIG. 1B A diagram contrasting the apparent mode of action of these antibodies is shown in Figure IB.
• Figures 2A and 2B show a comparison between 1G4 and 14B10 in their ability to bind the complex of HER3 ECD with heregulin. As shown in Figure 2A, 1G4 is able to bind the complex differentially, whereas 14B10 ( Figure 2B) does not.
• MCF-7 cells were maintained in log phase and for testing the medium was aspirated and the cells were rinsed, 2-3 ml of trypsin was added and the mixture incubated at 37 0 C for 5 minutes. Trypsinization was stopped by adding 10-12 ml of growth medium and the cells were suspended for counting using a Becton Dickenson Vi-CELLTM cell counter and then plated at 10 4 cells/well in 96-well plates at 100 ⁇ l/well. The plates were centrifuged at 960 rpm for 5 minutes and incubated at 37 0 C for 4 hours, after which the medium was replaced with serum- free medium at 100 ⁇ l/well and the cells returned to the incubator for 3 days.
• a 96-well Greiner plate was coated with 2 ⁇ g/ml capture antibody in PBS at 100 ⁇ l/well and incubated at 4 0 C overnight. The plate was then washed with PBST, blocked with 200 ⁇ l/well 3% BSA and PBS, washed twice with 300 ⁇ l PBST. Eighty ⁇ l of the cell lysate prepared in the previous paragraph was added to each well and incubated at room temperature with a rotator for 2 hours. The plate was then washed with PBST and then incubated with anti-phosphotyrosine labeled with horseradish peroxidase at 1:2000 for 2 hours.
• LumiGloTM peroxidase solution KPL catalog number 54-61-00 was added at 100 ⁇ l/well and the extent of phosphorylation determined spectraphotometrically. The results are shown in Figure 3 A. As shown in these results, the IC50 for 1G4 is about 10 ng/ml; whereas that for two other antibodies, E7 and C31 , was much higher.
• MCF-7 cells were grown in flasks until confluent, then trypsinized and collected in growing media to stop trypsinization. The cells were then washed with starving media 3-4 times.
• Sterile 96-well black clear-bottom plates were provided with 50 ⁇ l of starving media per well and incubated for 15 minutes at 37 0 C.
• the antibodies to be tested were diluted as desired in starving medium and seeded at 5,000 cells/50 ⁇ l into individual wells. The cells were incubated with antibody for 30 minutes at 37 0 C and then 3 nM HRG added.
• the cells were then cultured for 5-6 days and cell proliferation measured by adding fluorescent dye ResazurinTM at 1 :10 and incubated for 3 hours at 37 0 C.
• the plates were read on a fluorescent plate reader at 531/590 nm. The results are shown in Figure 3B.
• 1G4 had an EC50 between 0.1 ⁇ g/ml and 1 ⁇ g/ml; only 14B10 had a lower EC50.
• the novel antibodies also inhibit tyrosine proliferation in a cell line that over- expresses HERl and HER3, with no detectable HER2: MB468, human breast adenocarcinoma (Moasser, M. M., et al, Cancer Res (2001) 61 :7184-7188).
• the cells were plated at 5,000 cells in 100 ⁇ l in DMEM/F12 50/50 plus 0.02% BSA-Transferrin. Under these conditions, titration of heregulin stimulation of proliferation established that 3 nM achieves 80% of the maximal stimulation. Antibody inhibition was thereby measureable along the linear dose/response part of the stimulation curve.
• the cells were cultured for 5 days and cell proliferation measured by adding fluorescent dye ResazurinTM as in the previous Example. The results are shown in Figure 6. As shown, IG4, 14B10 and A28 have similar ECso's at approximately 10 "3 -10 "2 ⁇ g/ml. PlGl, however, has an EC50 of about 10 "1 ⁇ g/ml. Activity of the antibodies was then verified at 30 nM heregulin stimulation.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• Oncology (AREA)
• General Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=43032570

Family Applications (1)

Country Status (7)

Cited By (20)

Families Citing this family (9)

Citations (7)

Family Cites Families (5)

• 2010
  • 2010-04-29 AU AU2010242914A patent/AU2010242914B2/en not_active Ceased
  • 2010-04-29 JP JP2012508753A patent/JP2012525432A/ja active Pending
  • 2010-04-29 EP EP10770384A patent/EP2425009A4/en not_active Ceased
  • 2010-04-29 US US12/770,674 patent/US8362215B2/en not_active Expired - Fee Related
  • 2010-04-29 WO PCT/US2010/033058 patent/WO2010127181A1/en not_active Ceased
  • 2010-04-29 CA CA2759792A patent/CA2759792A1/en not_active Abandoned
• 2011
  • 2011-10-27 IL IL216014A patent/IL216014A0/en unknown
• 2013
  • 2013-01-17 US US13/744,299 patent/US8828388B2/en not_active Expired - Fee Related
• 2014
  • 2014-09-02 US US14/475,348 patent/US9321839B2/en active Active

Patent Citations (7)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events